LIVE Programme CEST time
BRIEF ORAL COMMUNICATION:
16:40-16:50 Tonic T-Cell Receptor Signaling Is Leukemogenic While Its Telmo A. Catarino (Porto)
Antigenic Stimulation Suppresses Leukemia Development
16:50-17:20 Panel discussion
17:20-17:30 Break
SESSION III – MINIMAL RESIDUAL DISEASE MONITORING
Chairs: Sabina Chiaretti (Rome) & Selina Luger (Philadelphia)
17:30-17:35 Introduction Sabina Chiaretti & Selina Luger
17:35-17:50 Euro MRD Activities Beat Schäfer (Zurich)
17:50-18:05 Which MRD for ALL Treatment Stratification? Monika Brüggemann (Kiel)
18:05-18:20 IG-TCR versus BCR-ABL1 MRD in Ph+ ALL Jan Zuna (Prague)
BRIEF ORAL COMMUNICATION:
18:20-18:30 Knockout of HMGN1 In Vivo reduces CRLF2r down Syndrome Elyse Page (Adelaide)
Acute Lymphoblastic Leukaemia Burden and Increases Survival
Outcomes
18:30-19:00 Panel discussion
19:00 Mentored Poster Walk #1
Poster Leaders: Richard Burt (London) & Anna Castleton (Manchester)
Saturday, May 8th, 2021
10:30-11:30 2 Simultaneous Meet the Expert sessions (non clinical)
- Role of HSCT in Ph+ ALL: Oliver Ottmann & Hervé Dombret
- Monitoring L-asparaginase Efficacy in ALL Patients: Mathilde Hunault & Adele Fielding
11:30-12:30 Mentored Poster Walk #2
Poster Leaders: Bela Wrench (London) & Charles de Bock (Sydney)
12:30-13:30 Lunch
SESSION IV – INDIVIDUALIZED MANAGEMENT OF ALL
Chairs: Nicola Gökbuget (Frankfurt) & Elizabeth Raetz (New York)
13:30-13:35 Introduction Nicola Gökbuget & Elizabetch Raetz
13:35-13:50 Treatment Issues in Teenagers and Young Adults ALL Rachael Hough (London)
2